Histologic or cytologic diagnosis of pancreatic adenocarcinoma (locally advanced disease that is not surgically resectable, or distant metastatic disease)

Participants must have measurable disease as per Response Evaluation Criteria In Solid Tumors (RECIST) guidelines

Participants must not have received prior chemotherapy, immunotherapy or chemoradiotherapy for advanced pancreas cancer

Karnofsky performance status (KPS) of 70-100

Adequate hematologic, hepatic and renal function

A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

What this study is about